<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Teprotumumab: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Teprotumumab: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Teprotumumab: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="126936" href="/d/html/126936.html" rel="external">see "Teprotumumab: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F54156081"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Tepezza</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F54046998"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Insulin-Like Growth Factor-1 Receptor (IGF-1R) Antagonist;</li>
<li>
                        Monoclonal Antibody</li></ul></div>
<div class="block doa drugH1Div" id="F54102762"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> If an infusion-related reaction occurred with a prior dose, administer subsequent infusions at a slower rate, and/or consider premedication with an antihistamine, antipyretic, and/or corticosteroid.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="27c26744-c3f9-4483-b251-c64b4a51b7e5">Thyroid eye disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Thyroid eye disease:</b>
<b>IV:</b> 10 mg/kg as a single dose, followed by 20 mg/kg every 3 weeks for 7 additional doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31971679','lexi-content-ref-28467880']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31971679','lexi-content-ref-28467880'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F54102764"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, there are no significant differences in the pharmacokinetics of teprotumumab in patients with CrCl ≥30 mL/minute.</p></div>
<div class="block doha drugH1Div" id="F54102765"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block doe drugH1Div" id="F54102763"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block arsc drugH1Div" id="F55427140"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Hearing impairment</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Hearing impairment<b> (auditory impairment) </b>has been reported with teprotumumab<b>.</b> Autophony, <b>deafness, eustachian tube disease, hearing loss</b>, <b>hyperacusis</b>, <b>hypoacusis</b>, <b>sensorineural hearing loss</b>, and <b>tinnitus </b>have been reported and may be irreversible despite discontinuation of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35418378','lexi-content-ref-35509619']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35418378','lexi-content-ref-35509619'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Not clearly established; inhibition of insulin-like growth factor-1 (IGF-1), which regulates the development, maintenance, and protection of hearing within the inner ear, may be a possible mechanism (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35418378','lexi-content-ref-35509619']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35418378','lexi-content-ref-35509619'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; tinnitus has been reported by the second dose and hearing loss after the fifth dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35418378','lexi-content-ref-35509619']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35418378','lexi-content-ref-35509619'])">Ref</a></span>). Hearing loss has also been reported 10 days after the first dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37034380']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37034380'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors: </i></p>
<p style="text-indent:-2em;margin-left:6em;">• History of ontological insult, including age-related hearing loss, loud noise exposure, and other conditions that degrade baseline hearing function (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35418378']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35418378'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent ototoxic medications (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35418378']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35418378'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hyperglycemia</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hyperglycemia</b> or increased blood glucose commonly occurred during clinical trials. Hyperglycemia occurred more frequently in patients with preexisting diabetes or impaired glucose tolerance; these patients were also more likely to develop grade 3 or grade 4 hyperglycemia. Hyperglycemia was able to be controlled after adjustment of medication for diabetes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28467880']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28467880'])">Ref</a></span>). Patients without diabetes experienced intermittent grade 1 hyperglycemia at a rate similar to placebo (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28467880']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28467880'])">Ref</a></span>). No evidence of residual worsening of glycemic control was seen after completion of the teprotumumab regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32205652','lexi-content-ref-28467880']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32205652','lexi-content-ref-28467880'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related; teprotumumab binds to insulin-like growth factor-1 receptor inhibitor (IGF-1R) and blocks its activation and signaling. Because teprotumumab shows no detectable affinity for insulin receptors, hyperglycemia is hypothesized to result from IGF-IR inhibition (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28467880']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28467880'])">Ref</a></span>). Inhibition of IGF-1R may result in a reduction in feedback inhibition of growth hormone secretion; as a result, growth hormone is elevated which can cause insulin resistance and increased gluconeogenesis and subsequent hyperglycemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24033707']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24033707'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; occurred within 21 days after the last dose in one clinical trial (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31971679']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31971679'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Preexisting diabetes; <b>Note: </b>In clinical trials, two-thirds of patients who developed hyperglycemia had impaired glucose tolerance or preexisting diabetes at baseline.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Infusion reactions</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Infusion-related reactions</b> frequently occurred in clinical trials (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31971679']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31971679'])">Ref</a></span>); reported symptoms include transient increases in blood pressure, feeling hot, tachycardia, dyspnea, headache, and muscular pain. Reported infusion reactions are usually mild or moderate in severity and resolve with treatment. A grade 2 nonanaphylactic reaction following the first dose that resulted in drug discontinuation has been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31971679']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31971679'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Rapid; may occur during or within 1.5 hours after any infusion.</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F54047357"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adults.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia (13%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Amenorrhea (≤23%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea (12%), nausea (17%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Dysmenorrhea (≤23%), uterine hemorrhage (≤23%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Fatigue (12%; including asthenia)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Muscle spasm (25%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Nail disease (5%; including nail discoloration and onychoclasis), xeroderma (8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hyperglycemia (10%)<span class="lexi-table-link-container"> (<a aria-label="Hyperglycemia table link" class="lexi-table-link" data-table-id="lexi-content-hyperglycemia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-hyperglycemia')">table 1</a>)</span><span class="table-link" style="display:none;">Hyperglycemia</span>, weight loss (6%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Hyperglycemia" frame="border" id="lexi-content-hyperglycemia" rules="all">
<caption style="text-align:center;">
<b>Teprotumumab: Adverse Reaction: Hyperglycemia</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Teprotumumab)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Teprotumumab)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">10%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">84</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">86</p></td>
<td align="left">
<p style="text-indent:0em;">2/3 of studied patients had preexisting diabetes or impaired glucose intolerance</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Dysgeusia (8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Infusion-related reaction (~4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache (8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Auditory impairment (10%; including autophony, deafness, hearing loss, eustachian tube disease, hyperacusis, hypoacusis, sensorineural hearing loss, and tinnitus)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Diabetes mellitus with hyperosmolar coma (Shah 2022), diabetic ketoacidosis</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Ulcerative colitis (Safo 2021)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Cognitive dysfunction (Hoang 2021), encephalopathy (Yee 2023)</p></div>
<div class="block coi drugH1Div" id="F54046890"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">There are no contraindications listed in the manufacturer's labeling.</p></div>
<div class="block war drugH1Div" id="F54102753"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Disease-related concerns:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Inflammatory bowel disease: Use may exacerbate preexisting inflammatory bowel disease (IBD). Monitor patients with IBD for flare of disease and discontinue use if IBD exacerbation is suspected.</p></div>
<div class="block foc drugH1Div" id="F54156082"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Tepezza: teprotumumab-trbw 500 mg (1 ea)</p></div>
<div class="block geq drugH1Div" id="F54156080"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F54172945"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Tepezza Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg (per each): $19,104.36</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F54102766"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">IV: Infuse over 90 minutes for the first 2 infusions; may reduce infusion time to 60 minutes for subsequent infusions if well tolerated. Do <b>NOT</b> administer as IV push or bolus.</p></div>
<div class="block use drugH1Div" id="F54046889"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Thyroid eye disease:</b> Treatment of thyroid eye disease regardless of thyroid eye disease activity or duration.</p></div>
<div class="block cyt drugH1Div" id="F54084965"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F54084962"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Efgartigimod Alfa: May diminish the therapeutic effect of Fc Receptor-Binding Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rozanolixizumab: May diminish the therapeutic effect of Fc Receptor-Binding Agents.<i> Risk C: Monitor therapy</i></p></div>
<div class="block rep_considerations drugH1Div" id="F54103021"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Females of reproductive potential should use effective contraception prior to treatment, during therapy and for 6 months after the last dose of teprotumumab.</p></div>
<div class="block pri drugH1Div" id="F54103020"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Teprotumumab is a humanized monoclonal antibody (IgG1). Placental transfer of human IgG is dependent upon the IgG subclass, maternal serum concentrations, birth weight, and gestational age, generally increasing as pregnancy progresses. The lowest exposure would be expected during the period of organogenesis (Palmeira 2012; Pentsuk 2009).</p>
<p style="text-indent:0em;margin-top:2em;">Based on the mechanism of action, and data from animal reproduction studies, in utero exposure to teprotumumab may cause fetal harm.</p></div>
<div class="block brc drugH1Div" id="F54103022"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">It is not known if teprotumumab is present in breast milk.</p></div>
<div class="block mop drugH1Div" id="F54102768"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Assess hearing prior to initiation, during, and after treatment; signs and symptoms of infusion reactions (eg, increased BP, feeling hot, tachycardia, dyspnea, headache, muscular pain); blood glucose and symptoms of hyperglycemia prior to infusion and during treatment; ensure proper glucose control in patient with hyperglycemia or pre-existing diabetes mellitus prior to initiation and during treatment.</p>
<p style="text-indent:-2em;margin-left:2em;">Monitor patients with IBD for disease exacerbations.</p></div>
<div class="block pha drugH1Div" id="F54102757"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Teprotumumab's mechanism of action in patients with thyroid eye disease has not been fully characterized. Teprotumumab binds to insulin-like growth factor-1 receptor and blocks its activation and signaling.</p></div>
<div class="block phk drugH1Div" id="F54102758"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub> (two-compartment model): Central: 3.26 ± 0.87 L; Peripheral: 4.32 ± 0.67 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Expected to undergo metabolism via proteolysis.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 20 ± 5 days.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F58215939"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Tepezza</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-35418378">
<a name="35418378"></a>Chow A, Silkiss RZ. Teprotumumab-associated chronic hearing loss screening and proposed treatments. <i>BMJ Case Rep</i>. 2022;15(4):e248335. doi:10.1136/bcr-2021-248335<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/teprotumumab-drug-information/abstract-text/35418378/pubmed" id="35418378" target="_blank">35418378</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31971679">
<a name="31971679"></a>Douglas RS, Kahaly GJ, Patel A, et al. Teprotumumab for the treatment of active thyroid eye disease. <i>N Engl J Med</i>. 2020;382(4):341-352. doi:10.1056/NEJMoa1910434.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/teprotumumab-drug-information/abstract-text/31971679/pubmed" id="31971679" target="_blank">31971679</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33972303">
<a name="33972303"></a>Hoang TD, Nguyen NT, Chou E, Shakir MK. Rapidly progressive cognitive decline associated with teprotumumab in thyroid eye disease. <i>BMJ Case Rep</i>. 2021;14(5):e242153. doi:10.1136/bcr-2021-242153<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/teprotumumab-drug-information/abstract-text/33972303/pubmed" id="33972303" target="_blank">33972303</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32205652">
<a name="32205652"></a>Hwang CJ, Eftekhari K. Teprotumumab for thyroid eye disease. <i>Int Ophthalmol Clin</i>. 2020;60(2):47-55. doi:10.1097/IIO.0000000000000307<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/teprotumumab-drug-information/abstract-text/32205652/pubmed" id="32205652" target="_blank">32205652</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37034380">
<a name="37034380"></a>Lu TJ, Amarikwa L, Winn BJ, Inserra M, Dosiou C, Kossler AL. Oral corticosteroids for teprotumumab-related hearing loss: a case report. <i>Case Rep Ophthalmol</i>. 2023;14(1):134-139. doi:10.1159/000529422<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/teprotumumab-drug-information/abstract-text/37034380/pubmed" id="37034380" target="_blank">37034380</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24033707">
<a name="24033707"></a>Ma H, Zhang T, Shen H, Cao H, Du J. The adverse events profile of anti-IGF-1R monoclonal antibodies in cancer therapy. <i>Br J Clin Pharmacol</i>. 2014;77(6):917-928. doi:10.1111/bcp.12228<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/teprotumumab-drug-information/abstract-text/24033707/pubmed" id="24033707" target="_blank">24033707</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35509619">
<a name="35509619"></a>Najjar W, Yu J. Audiologic demonstration of ototoxicity from teprotumumab treatment in a patient with thyroid eye disease. <i>OTO Open</i>. 2022;6(2):2473974X221097097. doi:10.1177/2473974X221097097<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/teprotumumab-drug-information/abstract-text/35509619/pubmed" id="35509619" target="_blank">35509619</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22235228">
<a name="22235228"></a>Palmeira P, Quinello C, Silveira-Lessa AL, Zago CA, Carneiro-Sampaio M. IgG placental transfer in healthy and pathological pregnancies. <i>Clin Dev</i>
<i>Immunol</i>. 2012;2012:985646. doi:10.1155/2012/985646.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/teprotumumab-drug-information/abstract-text/22235228/pubmed" id="22235228" target="_blank">22235228</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19626656">
<a name="19626656"></a>Pentsuk N, van der Laan JW. An interspecies comparison of placental antibody transfer: new insights into developmental toxicity testing of monoclonal antibodies. <i>Birth Defects Res B Dev Reprod Toxicol</i>. 2009;86(4):328-344. doi:10.1002/bdrb.20201.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/teprotumumab-drug-information/abstract-text/19626656/pubmed" id="19626656" target="_blank">19626656</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33817409">
<a name="33817409"></a>Safo MB, Silkiss RZ. A case of ulcerative colitis associated with teprotumumab treatment for thyroid eye disease. <i>Am J Ophthalmol Case Rep</i>. 2021;22:101069. doi:10.1016/j.ajoc.2021.101069<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/teprotumumab-drug-information/abstract-text/33817409/pubmed" id="33817409" target="_blank">33817409</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35959086">
<a name="35959086"></a>Shah K, Charitou M. A novel case of hyperglycemic hyperosmolar state after the use of teprotumumab in a patient with thyroid eye disease. <i>AACE Clin Case Rep</i>. 2022;8(4):148-149. doi:10.1016/j.aace.2022.01.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/teprotumumab-drug-information/abstract-text/35959086/pubmed" id="35959086" target="_blank">35959086</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28467880">
<a name="28467880"></a>Smith TJ, Kahaly GJ, Ezra DG, et al. Teprotumumab for thyroid-associated ophthalmopathy. <i>N Engl J Med</i>. 2017;376(18):1748-1761. doi:10.1056/NEJMoa1614949.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/teprotumumab-drug-information/abstract-text/28467880/pubmed" id="28467880" target="_blank">28467880</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Tepezza.2020.01">
<a name="Tepezza.2020.01"></a>Tepezza (teprotumumab) [prescribing information]. Deerfield, IL: Horizon Therapeutics USA Inc; July 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37141481">
<a name="37141481"></a>Yee MD, McCarthy J, Quinn B, Surani A. Teprotumumab-induced encephalopathy: a rare side effect of a novel therapeutic. <i>WMJ</i>. 2023;122(2):134-137.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/teprotumumab-drug-information/abstract-text/37141481/pubmed" id="37141481" target="_blank">37141481</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 126630 Version 60.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
